Pacific Edge Limited announced that it had substantially completed a commercial agreement with Te Whatu Ora - Southern for the use of its non-invasive Cxbladder genomic biomarker tests. At this stage the contract remains unsigned. The business case is currently with Te Whatu Ora -Southern Management Team and following that it will enter an approvals cycle.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.09 NZD | +2.27% |
|
-4.26% | -23.08% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.08% | 43.61M | |
+24.97% | 52.73B | |
+37.49% | 39B | |
-8.98% | 38.52B | |
+27.93% | 30.38B | |
-12.26% | 26.39B | |
+10.32% | 26.08B | |
+44.70% | 14.15B | |
+32.59% | 12.6B | |
-6.43% | 11.51B |
- Stock Market
- Equities
- PEB Stock
- News Pacific Edge Limited
- Pacific Edge Limited Completes a Commercial Agreement with Te Whatu Ora Southern